Skip to main content
. 2020 Nov 27;11:6082. doi: 10.1038/s41467-020-19842-2

Fig. 6. MiCas9’s beneficial effects are Brex27 and RAD51 dependent.

Fig. 6

a Indel rates by spCas9, miCas9, and miCas9-mutant at the on-target site for sg-AAVS1 and the off-target site 1 for sg-EMX1. b Indel rates estimated by T7E1 assay by spCas9 and miCas9 with or without the use of RAD51 inhibitor, B02. c Co-IP results by using anti-flag (left) or anti-RAD51 (right) antibodies followed western blot for RAD51 or Cas9. d ChIP assay results with anti-RAD51 antibody at the proximal region of the sg-AAVS1 target locus. Sp: spCas9, Mi: miCas9, Mi-mut: miCas9-mutant. #Reads: Average amplicon reads per sample. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM). Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Source data are available in the Source Data file.